Want to see HK:2170 full AI Analyst Report?
Top Page
Suzhou Basecare Medical Corp. Ltd. Class H
(2170)
Select Model
Select Model
Rating:44Neutral
Price Target:
HK$1.00
▼(-49.24% Downside)
Action:Reiterated
Date:09/30/26
The score is primarily held back by weak financial performance—large ongoing losses, persistent negative operating/free cash flow, and a notable 2025 revenue decline. Technicals add further pressure with a multi-timeframe downtrend and bearish momentum. Valuation provides only limited offset because the negative P/E reflects unprofitability and no dividend yield is available.
Positive Factors
Solid Gross Margin
A gross margin near 48% shows that the company retains meaningful value after product costs, providing a foundation for future operating improvement. If revenue stabilizes and expenses become better aligned with sales, this underlying product economics could support a path toward stronger profitability.
Negative Factors
Revenue Contraction
The sharp 2025 revenue decline interrupts the earlier period of meaningful scaling and raises concern about near-term demand momentum. Sustained contraction would reduce operating leverage, limit reinvestment capacity, and make it harder for fixed research, commercial, and corporate costs to be absorbed.
Read all positive and negative factors
Positive Factors
Negative Factors
Solid Gross Margin
A gross margin near 48% shows that the company retains meaningful value after product costs, providing a foundation for future operating improvement. If revenue stabilizes and expenses become better aligned with sales, this underlying product economics could support a path toward stronger profitability.
Read all positive factors
Suzhou Basecare Medical Corp. Ltd. Class H (2170) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$346.01M
Dividend YieldN/A
Average Volume (3M)60.02K
Price to Earnings (P/E)―
Beta (1Y)0.69
Revenue Growth-2.28%
EPS Growth24.76%
CountryHK
Employees388
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)-0.64
Shares Outstanding82,713,840
10 Day Avg. Volume72,600
30 Day Avg. Volume60,016
Financial Highlights & Ratios
PEG Ratio0.35
Price to Book (P/B)0.49
Price to Sales (P/S)1.96
P/FCF Ratio-1.88
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.23
Revenue Forecast (FY)HK$412.00M
Suzhou Basecare Medical Corp. Ltd. Class H Business Overview & Revenue Model
Company Description
Suzhou Basecare Medical Corporation Limited, an investment holding company established in Suzhou, China, in 2010, focuses its business activities within the People's Republic of China. The company primarily engages in the research, development, an...
How the Company Makes Money
The company makes money primarily by selling medical devices and consumable products used in assisted reproduction and fertility treatment workflows (e.g., IVF-related devices and supporting consumables) to institutional healthcare customers such ...
Suzhou Basecare Medical Corp. Ltd. Class H Financial Statement Overview
Summary
Income Statement
28
Negative
Balance Sheet
62
Positive
Cash Flow
24
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 260.68M | 233.27M | 299.11M | 207.98M | 140.90M | 107.30M |
| Gross Profit | 139.75M | 123.61M | 136.22M | 91.35M | 59.53M | 51.15M |
| EBITDA | -100.14M | -162.43M | -232.10M | -174.14M | -117.73M | -118.88M |
| Net Income | -174.03M | -223.46M | -237.03M | -191.69M | -123.16M | -143.65M |
Balance Sheet | ||||||
| Total Assets | 1.33B | 1.45B | 1.67B | 1.90B | 1.78B | 1.80B |
| Cash, Cash Equivalents and Short-Term Investments | 378.43M | 447.34M | 684.63M | 945.71M | 1.33B | 1.52B |
| Total Debt | 342.35M | 343.51M | 328.42M | 281.92M | 75.54M | 48.57M |
| Total Liabilities | 468.21M | 512.00M | 527.47M | 499.98M | 188.33M | 85.85M |
| Stockholders Equity | 864.78M | 935.06M | 1.14B | 1.40B | 1.59B | 1.72B |
Cash Flow | ||||||
| Free Cash Flow | -132.51M | -243.37M | -322.41M | -371.44M | -317.52M | -234.71M |
| Operating Cash Flow | -97.88M | -160.01M | -229.12M | -267.23M | -188.77M | -197.85M |
| Investing Cash Flow | -44.37M | -5.33M | -181.19M | -324.81M | -88.70M | -56.60M |
| Financing Cash Flow | -1.77M | 16.13M | 33.78M | 190.55M | 23.51M | 1.60B |
Suzhou Basecare Medical Corp. Ltd. Class H Technical Analysis
Negative
1.97
Price Trends
1.36
Negative
1.39
Negative
1.68
Negative
Market Momentum
-0.03
Positive
40.45
Neutral
34.80
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2170, the sentiment is Negative. The current price of 1.97 is above the 20-day moving average (MA) of 1.31, above the 50-day MA of 1.36, and above the 200-day MA of 1.68, indicating a bearish trend. The MACD of -0.03 indicates Positive momentum. The RSI at 40.45 is Neutral, neither overbought nor oversold. The STOCH value of 34.80 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:2170.
Suzhou Basecare Medical Corp. Ltd. Class H Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | HK$5.26B | 11.89 | 13.24% | 2.49% | 16.15% | 31.89% | |
59 Neutral | HK$5.70B | 87.75 | 1.71% | ― | 0.75% | -20.22% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | HK$1.63B | -0.86 | -6.69% | ― | ― | ― | |
46 Neutral | HK$11.65B | 31.22 | 6.07% | 0.06% | -3.62% | ― | |
45 Neutral | HK$518.19M | -0.92 | -28.24% | ― | -38.15% | 25.70% | |
44 Neutral | HK$346.01M | -1.69 | -19.34% | ― | -2.28% | 24.76% |
* Healthcare Sector Average
HK:2170
Suzhou Basecare Medical Corp. Ltd. Class H
1.24
-1.77
-58.80%
HK:0853
MicroPort Scientific
6.08
-8.75
-59.01%
HK:1302
LifeTech Scientific Corporation
1.31
-0.83
-38.79%
HK:1789
AK Medical Holdings Ltd.
4.74
-0.70
-12.86%
HK:2160
MicroPort CardioFlow Medtech Corp.
1.28
-5.97
-82.34%
HK:2500
Venus Medtech (Hangzhou), Inc. Class H
1.14
-2.08
-64.60%
Suzhou Basecare Medical Corp. Ltd. Class H Corporate Events
Basecare Wins NMPA Nod for New Embryo Cryopreservation Reagents
Sep 15, 2026
Suzhou Basecare Medical Corporation Limited has received National Medical Products Administration approval for Class III medical device registration certificates for its Gems Vitrification Set and Warming Set, key reagents used in embryo cryoprese...
Suzhou Basecare Narrows Losses and Secures Landmark PGT Approvals in China
Aug 28, 2026
Suzhou Basecare Medical Corporation Limited reported interim unaudited results for the six months ended 30 June 2026, with revenue rising 27.0% year on year to RMB128.7 million and losses narrowing significantly, as loss attributable to shareholde...
Suzhou Basecare Board to Review Interim Results and Possible Dividend
Aug 18, 2026
Suzhou Basecare Medical Corporation Limited, a Hong Kong-listed healthcare company based in Suzhou, operates through a group structure that includes several subsidiaries and is governed by a board made up of executive, non-executive and independen...
Suzhou Basecare Cuts Losses as Genetic Testing and Culture Media Drive Revenue Surge
Aug 16, 2026
Suzhou Basecare Medical Corporation Limited expects significant improvement in its interim 2026 results, with revenue projected to rise to about RMB125.7 million to RMB130.8 million, a 24% to 29% increase year-on-year. The loss attributable to equ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.